An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.

Saved in:
Bibliographic Details
Title: An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Authors: Cheng LS; Department of Geriatrics, The First Affiliated Hospital of University of Science and Technology of China, Gerontology Institute of Anhui Province, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China.; Hefei HankeMab Biotechnology Limited, Hefei, 230088, Anhui, China.; Anhui Provincial Key Laboratory of Tumor Immunotherapy and Nutrition Therapy, Hefei, 230001, Anhui, China.; Anhui Province Key Laboratory of Gene Engineering Pharmaceutical, Biomedicine Technology Innovation Center of Hefei, Anhui Anke Biotechnology (Group) Co., Ltd., Hefei, 230088, Anhui, China., Zhu M; School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, Anhui, China., Gao Y; School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, Anhui, China., Liu WT; Hefei HankeMab Biotechnology Limited, Hefei, 230088, Anhui, China., Yin W; Department of Geriatrics, The First Affiliated Hospital of University of Science and Technology of China, Gerontology Institute of Anhui Province, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China.; Anhui Provincial Key Laboratory of Tumor Immunotherapy and Nutrition Therapy, Hefei, 230001, Anhui, China., Zhou P; Hefei HankeMab Biotechnology Limited, Hefei, 230088, Anhui, China., Zhu Z; School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, Anhui, China., Niu L; School of Life Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230026, Anhui, China., Zeng X; Hefei HankeMab Biotechnology Limited, Hefei, 230088, Anhui, China., Zhang D; Hefei HankeMab Biotechnology Limited, Hefei, 230088, Anhui, China., Fang Q; Hefei HankeMab Biotechnology Limited, Hefei, 230088, Anhui, China., Wang F; Hefei HankeMab Biotechnology Limited, Hefei, 230088, Anhui, China., Zhao Q; Hefei HankeMab Biotechnology Limited, Hefei, 230088, Anhui, China., Zhang Y; School of Health Service Management, Anhui Medical University, Hefei, 230032, Anhui, China. zhangymail@ahmu.edu.cn., Shen G; Department of Geriatrics, The First Affiliated Hospital of University of Science and Technology of China, Gerontology Institute of Anhui Province, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, 230001, Anhui, China. gdshen@ustc.edu.cn.; Anhui Provincial Key Laboratory of Tumor Immunotherapy and Nutrition Therapy, Hefei, 230001, Anhui, China. gdshen@ustc.edu.cn.
Source: Cellular & molecular biology letters [Cell Mol Biol Lett] 2023 May 31; Vol. 28 (1), pp. 47. Date of Electronic Publication: 2023 May 31.
Publication Type: Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 9607427 Publication Model: Electronic Cited Medium: Internet ISSN: 1689-1392 (Electronic) Linking ISSN: 14258153 NLM ISO Abbreviation: Cell Mol Biol Lett Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Be the first to leave a comment!
You must be logged in first